ArticleFrontiers in medicine2026
Voclosporin shows protective effect and intestinal barrier enforcement in experimental colitis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of inflammatory bowel disease (IBD) is still challenging. Therefore, it is crucial not only to develop new drugs specifically targeting IBD but also to evaluate the application and efficacy of already established pharmaceuticals used for related disorders. A promising new candidate is Voclosporin (Voc), a recently approved drug for lupus nephritis. In this study, we aimed to further elucidate the efficiency and the molecular mechanism of action of Voclosporin in comparison with its analogon cyclosporine A (CsA). Using an experimental colitis model and human PBMCs, we performed a comprehensive analysis including mini-endoscopy, histopathology, multi-photon endomicroscopy (MPEM), immunofluorescence staining, flow cytometry, and cytokine secretion profiling of murine lamina propria mononuclear cells (LPMCs). Treatment with Voc or CsA improved colitis-associated weight loss and reduced intestinal inflammation as assessed by endoscopy and histopathological stainings. Treatment with Voclosporin led to a significant increase of the barrier-strengthening protein claudin 3 in the colon of mice with experimentally induced colitis. Furthermore, treatment of stimulated human-derived PBMCs from healthy controls with Voclosporin and CsA inhibited the activation of IL2-inducible tyrosine kinase ITK, a known trigger of inflammation in IBD. These results further support the potential of Voclosporin as a promising therapeutic strategy for the treatment of acute intestinal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.